Clinical predictors of bevacizumab-associated gastrointestinal perforation

Gynecologic Oncology

Volumn 120, Issue 3, 2011, Pages 464-469

  Tanyi, Janos L ^a   McCann, Georgia ^a   Hagemann, Andrea R ^a   Coukos, George ^a   Rubin, Stephen C ^a   Liao, John B ^a   Chu, Christina S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bevacizumab associated perforation; Gastrointestinal perforation; Ovarian cancer

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

ADULT; AGED; ARTICLE; BEVACIZUMAB ASSOCIATED GASTROINTESTINAL; BEVACIZUMAB ASSOCIATED GASTROINTESTINAL PERFORATION; BODY MASS; CANCER CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; ILEUS; INTESTINE OBSTRUCTION; INTESTINE SURGERY; LARGE INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OBESITY; OVARY CARCINOMA; PERITONEUM CANCER; PRIORITY JOURNAL; SMALL INTESTINE PERFORATION; SMOKING; STOMACH PERFORATION; THROMBOEMBOLISM; UTERINE TUBE CARCINOMA;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; HYPERTENSION; ILEUS; INTESTINAL PERFORATION; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 79951576333     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.11.009     Document Type: Article

References (27)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 4 2009 225 249
2. See H.T., and Kavanagh J.J. Novel agents in epithelial ovarian cancer Cancer Invest 22 Suppl 2 2004 29 44 (Pubitemid 40065218)
3. L. Martin, and R. Schilder Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition J Clin Oncol 25 20 2007 2894 2901 (Pubitemid 47123153)
4. A.A. Garcia, H. Hirte, G. Fleming, D. Yang, D.D. Tsao-Wei, and L. Roman Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia J Clin Oncol 26 1 2008 76 82
5. J.M. Jurado, A. Sánchez, B. Pajares, E. Pérez, L. Alonso, and E. Alba Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer Clin Transl Oncol 10 9 2008 583 586
6. S.A. Cannistra, U.A. Matulonis, R.T. Penson, J. Hambleton, J. Dupont, and H. Mackey Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 33 2007 5180 5186 (Pubitemid 350232248)
7. R.A. Burger Experience with bevacizumab in the management of epithelial ovarian cancer J Clin Oncol 25 20 2007 2902 2908 (Pubitemid 47123154)
8. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.I. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 33 2007 5165 5171 (Pubitemid 350237599)
9. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, and W. Heim Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2004 2335 2342 (Pubitemid 38702844)
10. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, and W. Heim Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 12 2007 1539 1544
11. A. Sandler, R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, and A. Dowlati Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 24 2006 2542 2550 (Pubitemid 44917502)
12. B.D. Badgwell, E.R. Camp, B. Feig, R.A. Wolff, C. Eng, and L.M. Ellis Management of bevacizumab-associated bowel perforation: a case series and review of the literature Ann Oncol 19 3 2008 577 582 (Pubitemid 351325682)
13. J.D. Wright, A. Hagemann, J.S. Rader, D. Viviano, R.K. Gibb, and L. Norris Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis Cancer 107 1 2006 83 89 (Pubitemid 43939034)
14. S. Hapani, D. Chu, and S. Wu Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis Lancet Oncol 10 6 2009 559 568
15. H.S. Nimeiri, A.M. Oza, R.J. Morgan, G. Friberg, K. Kasza, and L. Faoro Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia Gynecol Oncol 110 1 2008 49 55
16. B.J. Monk, E. Han, C.A. Josephs-Cowan, G. Pugmire, and R.A. Burger Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer Gynecol Oncol 102 2 2006 140 144 (Pubitemid 44056265)
17. Wright J.D., A. Alvarezsecord, Numnum T.M., R.P. Rocconi, M.A. Powell, and A. Berchuck A multi-institutional evaluation of the safety and efficacy of bevacizumab for recurrent, platinum-resistant ovarian cancer J Clin Oncol 24 18 S 2006 p. Abstract 5019
18. Friberg G., A.M. Oza, Morgan R.J., E.E. Vokes, D.R. Gandara, and G.F. Fleming Bevacizumab plus erlotinib for patient with recurrent ovarian and fallopian tube cancer: preliminary results of a multi-center phase II trial J Clin Oncol 24 18 S 2006 p. Abstract 5018
19. M.A. Bidus, J.C. Webb, J.D. Siedman, G.S. Rose, C.R. Boice, and J.C. Elkas Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms Gynecol Oncol 102 1 2006 5 7 (Pubitemid 43851062)
20. R.T. Penson, D.S. Dizon, S.A. Cannistra, M.R. Roche, C.N. Krasner, and S.T. Berlin Phase II study of carboplatin, paclitaxel and bevacizumab with maintenance bevacizumab as first line chemotherapy for advanced mullerian tumors J Clin Oncol 28 1 2010 154 159
21. J.P. Micha, B.H. Goldstein, M.A. Rettenmaier, M. Genesen, C. Graham, and K. Bader A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer Int J Gynecol Cancer 17 4 2007 771 776 (Pubitemid 47063333)
22. J.P. Diaz, W.P. Tew, O. Zivanovic, J. Konner, P.J. Sabbatini, and L.A. dos Santos Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma Gynecol Oncol 116 3 2010 335 339
23. Hedrick E., M. Kozloff, Hainsworth J., S. Badarinath, A. Cohn, and P. Flynn Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE) [meeting abstracts J Clin Oncol 24 18 S 2006 p. Abstract 3536
24. E.S. Han, and B.J. Monk What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer ? Gynecol Oncol 105 1 2007 3 6 (Pubitemid 46441477)
25. Burger R.A., Brady M.F., Bookman M.A., J.L. Walker, H.D. Homesley, and J. Fowler Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study J Clin Oncol 28 18 S 2010 LBA1
26. Perren T., A.M. Swart, J. Pfisterer, J. Ledermann, A. Lortholary, and G. Kristensen ICON: a phase III randomized gynaecologic cancer intergroup trial of concurrent bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC) Ann Oncol 21 8 S 2010 2 3 LBA4
27. Sugrue M., Kozloff M., Hainsworth J., S. Badarinath, A. Cohn, and P. Flynn Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy J Clin Oncol 24 18 S 2006 p. Abstract 3535